Name | LHF-535 |
Description | LHF-535 is an antiviral compound. It has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively. |
In vitro | LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 inhibits Lassa GP-pseudotyped lentivirus (IC50: 0.1-0.3 nM). LHF-535 shows effective antiviral activity against a broad array of hemorrhagic fever arenaviruses [2]. |
In vivo | An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection. LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protects mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver [2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 96.67 mg/mL (234.34 mM), Sonication is recommended. H2O : < 0.1 mg/mL (insoluble)
|
Keywords | inhibit | Arenavirus | LHF535 | LHF 535 | Inhibitor | LHF-535 |
Inhibitors Related | EIDD-1931 | Phenytoin sodium | Anthraquinone | Aspirin | Vorinostat | L-Lysine | 2-Phenylethanol | L-Lysine hydrochloride | (-)-Epicatechin gallate | PCL 016 | (-)-α-Pinene | 4-Phenylbutyric acid |
Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |